Ketamine clinic marketing

More consults and treatment starts, from ketamine clinic marketing

Medicare’s 2026 national rate for one Spravato session reaches $1,356.08, yet ads show on 1.1% of ketamine search volume, so we count starts from search, maps and AI answers.

Request the ketamine patient question sheet
Trusted by the world's fastest-growing brands

The economics

What a ketamine treatment start pays, and the price of winning one

Three sourced figures on each side. Medicare publishes what it allows for a Spravato session; IV infusion prices are each clinic’s own and vary widely.

What one treatment start is worth

Medicare, one Spravato session above 56 mgHCPCS G2083, 2026, national, non-facility, before geographic adjustment: 40.60 RVUs × $33.4009, esketamine and observation included.
$1,356.08
Medicare, one Spravato session of 56 mg or lessHCPCS G2082 on the same basis: 28.52 RVUs × $33.4009. The label’s induction phase is two sessions a week for four weeks.
$952.59
Published cash price, one IV ketamine infusionThe range among the 7 of 13 Maryland infusion advertisers that listed a price in March 2023. One state and one month, not a national average.
$360 to $2,500

What one costs to win

Cost per click, “ketamine therapy”110,000 searches a month. Of 332 patient searches with 100 or more a month, 262 show no click price; the 70 priced have a median of $4.81.
$7.18
Patient search volume where ads appearedAcross 10,503 ketamine therapy and clinic searches, 349,920 a month. Top-of-page ads appeared on less than 0.1%.
1.1%
LegitScript, telehealth or addiction advertisersYear one per website: $975 to apply plus $2,150 a year. Google asks for it only from telemedicine providers and addiction services.
$3,125

With ads on so little of the search volume, a clinic wins treatment starts through organic results, the map pack and AI answers. Each start leads to repeat sessions, so the work is judged on starts counted in the clinic’s own schedule.

Who we work with

Four kinds of ketamine practice, each judged on its own number

The treatment, who pays and who signs differ by practice. The right-hand column opens the service page that comes first for each.

PracticeWhat decides the returnRead first
Independent IV ketamine infusion clinicsCash-pay patients within driving distance who finish a consult and an induction series. A page about depression describes an off-label use.
Psychiatry practices offering SpravatoInsurance-billed patients who qualify, with benefits verified before the first session in a REMS-certified office.
Ketamine-assisted psychotherapy practicesClients ready for preparation and integration sessions. Oral and sublingual ketamine are compounded products FDA has not approved for any use.
Multi-site ketamine and interventional psychiatry groupsTreatment starts by office and service line, each office in its own map pack, and state rules such as Georgia’s license from July 1, 2027.

IV ketamine, Spravato and KAP each carry their own claims rules, so a group that offers all three needs a separate page set for each.

The rules

The FDA, FTC, DEA and ad rules behind IV ketamine and Spravato pages

Eight rules on what an infusion clinic or Spravato practice may claim, track and advertise, each as strong as its source.

  1. Off-label statusFDA safety alert

    Ketamine is not FDA-approved for any psychiatric disorder, so a page on IV ketamine for depression describes an off-label use.

    FDA approves ketamine as an IV or IM injection for anesthesia. Its October 2023 safety alert adds that it knows of no evidence that compounded ketamine is safer, more effective or faster than approved medications.

  2. Response ratesFTC guidance

    A response rate, “proven” or “safe and effective” needs trial evidence on file before the treatment page goes live.

    Before a health-benefit claim runs, the FTC expects competent and reliable scientific evidence, which it says generally means randomized controlled human trials. A rate is quoted only with its study, population and endpoint named, such as the ELEKT-D trial’s 403 patients referred for ECT.

  3. Spravato REMSFDA-approved label

    Spravato is given only in REMS-certified settings, with at least two hours of monitoring, and the spray never goes home.

    Spravato is approved for treatment-resistant depression and for depressive symptoms with acute suicidal ideation, through its REMS only. Its pages cannot borrow IV ketamine’s claims, and IV ketamine pages cannot borrow Spravato’s approval.

  4. Screening and booking tagsHHS guidance

    Consult, screening, booking and portal pages carry no ad or analytics tags.

    A screening answer passed to an ad platform tells it about a mental health condition. HHS treats a tracking vendor on a booking page as a business associate needing an agreement, and a federal court in 2024 set aside only HHS’s view of public pages.

  5. Prescription drug keywordsGoogle Ads policy

    Bidding on keywords that contain a prescription drug term needs Google’s approval, and Google’s monitored list names Ketalar.

    In the US, ads and landing pages may name prescription drugs. LegitScript and Google certification apply to telemedicine providers, such as a clinic that prescribes after a video visit, and to addiction services, not to every ketamine ad.

  6. Addiction treatmentGoogle policy and Part 2

    Ketamine for alcohol or opioid use disorder needs LegitScript addiction services certification before Google ads run.

    Google requires its own certification as well, and not every addiction service qualifies. A clinic that holds itself out as treating substance use disorder and is federally assisted, by Medicare participation or a DEA registration used for that treatment, becomes a Part 2 program.

  7. Telehealth prescribingDEA rule

    A DEA-registered practitioner may prescribe ketamine by telemedicine, with no in-person evaluation, through December 31, 2026.

    Ketamine is a Schedule III drug. The DEA’s fourth temporary extension runs to that date, and as of November 9, 2026 no further extension or final special-registration rule had been published, so a telehealth page carries the date.

  8. Georgia clinic licenseState statute

    Georgia requires clinics giving IV ketamine to hold a medical board license from July 1, 2027.

    HB 717 (Act 634) was signed May 12, 2026. The board’s rules, due by December 31, 2026, must cover truth in advertising about the credentials, education and training of whoever gives the treatment, so clinician pages state them exactly.

Services for ketamine clinics

Services that move consults and starts, from search to maintenance

Each entry opens the national service page, with a line on what changes for IV ketamine and Spravato. The groups follow a patient from the first search to a maintenance booking.

The playbook

A clinic playbook, measured in treatment starts

Each stage moves a number the clinic already keeps in its schedule, phone log or charts. The documents are worked samples for Sample Live Oak Ketamine Center, a fictional two-office clinic in Savannah, Georgia.

treatment-page-claims.csv

Treatment page claims, baseline

Sample · Sample Live Oak Ketamine Center
Check on 6 treatment pagesAt baselineChange
States which uses are off-label0 pagesAdd to each page
Calls ketamine FDA-approved2 pagesRemove
Response rate with no study named5 pagesName the study or cut
Calls ketamine nonaddictive1 pageRemove
The 90-day targets: off-label status stated on 6 of 6 pages, and FDA-approval wording on none.

A sample month

Sample Live Oak Ketamine Center, consults held by source

Consults held in an average month from June to August 2026, before the work began, and the treatment starts that followed. The clinic is fictional, with offices in Midtown Savannah and Pooler.

Sample Live Oak Ketamine CenterIntake report · Jun to Aug 2026 averageOrganic search34Map pack28Clinician referral30Word of mouth17Directories, AI, other17Consults held126Became treatment starts60 of 126 · 47.6%
  1. 01

    Search brought 62 consults with no ads running

    Organic results and the map pack brought 62 of the 126, almost half, while Google Ads sat paused after 9 ads were disapproved. Clinician referrals, at 30, led the sources outside search.

  2. 02

    Three smaller sources made up 17

    Directories brought 8, AI answers 5 and other sources 4, each recorded at intake. Before the work, the clinic was named in answers to 2 of 12 fixed patient questions across 4 AI engines.

  3. 03

    Under half of the consults held became starts

    60 of 126, or 47.6%, became treatment starts: 38 IV induction series and 22 Spravato courses. Screening turns some people away by design, so the medical director reads this rate with us.

Specialist or generalist

Where a ketamine-fluent agency works differently

Any agency can build a clinic site. These rows are where the work changes once a page describes a controlled substance used off-label; put each one to any agency you are weighing.

General agencyBuilt around channelsKetamine-fluent agencyBuilt around FDA status and patient data
Treatment claimsClaims drawn from the clinic’s brief and other clinics’ pagesOff-label status stated, and a response rate only with its study named
Spravato and IV pagesOne ketamine page covering each treatment the clinic givesSeparate pages, so Spravato’s approval never describes IV ketamine
Screening formsConversion tags placed on form submissionsNo ad or analytics tags on consult, screening or booking pages
Ad eligibilityCampaigns planned from keyword volume and budgetWhich services need Google approval or LegitScript, set out before any ad spend
Crisis callsCall answering scripted for bookingA written protocol that hands any mention of suicide to a person
What is reportedClicks, form fills and cost per leadConsults held, treatment starts and inductions completed, by source
Which one a ketamine clinic needs

A clinic that gives Spravato, prescribes by telehealth or treats addiction needs all six rows answered in writing. An infusion clinic that only wants new office photos and a refreshed profile can work with either.

Questions

Clinic owners’ questions, from FDA status to crisis calls

Short answers, each naming the rule or the study behind it.

Ketamine clinic statistics

Ketamine figures, from patients to advertising claims

Four of the 29 sourced figures. The statistics page links each one to the document it came from.

FigureWhat it measures
2.8 millionUS adults with treatment-resistant depression, claims-based estimate
58.8%Maryland ketamine advertisers not disclosing off-label use, 2023
36.5%New York-area clinics prescribing ketamine for at-home use, 2025
60.8%Ketamine search volume showing a Google AI Overview, 2026

All 29 ketamine clinic figures, with sources

Start here

See which clinics AI answers name for ketamine in your metro

Tell us your metro and the treatments you give. We put the questions patients ask, such as what IV ketamine costs in Denver, to ChatGPT and Google’s AI, and send a dated sheet of the clinics named.